Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating subcutaneously administered mosunetuzumab in systemic lupus erythematosus has completed its assessment of safety, tolerabili…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Mosunetuzumab (mosunetuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: COMPLETED